Alaunos Therapeutics, Inc. financial data

Symbol
TCRT on Nasdaq
Location
Fort Lauderdale, FL
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 14 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 273% % -40%
Debt-to-equity 39% % 40%
Return On Equity -168% % 37%
Return On Assets -121% % 42%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 2,231,829 shares 39%
Common Stock, Shares, Outstanding 2,205,846 shares 38%
Entity Public Float $10,801,553 USD -89%
Common Stock, Value, Issued $2,000 USD 0%
Weighted Average Number of Shares Outstanding, Basic 2,183,039 shares 36%
Weighted Average Number of Shares Outstanding, Diluted 2,183,039 shares 36%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $7,000 USD 17%
Research and Development Expense $914,000 USD -34%
General and Administrative Expense $3,165,000 USD -48%
Operating Income (Loss) $4,072,000 USD 66%
Nonoperating Income (Expense) $48,000 USD -79%
Net Income (Loss) Attributable to Parent $4,024,000 USD 66%
Earnings Per Share, Basic -2 USD/shares 82%
Earnings Per Share, Diluted -2 USD/shares 82%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $1,938,000 USD 15%
Assets, Current $2,685,000 USD -24%
Property, Plant and Equipment, Net $97,000 USD
Assets $3,724,000 USD 4.9%
Accounts Payable, Current $843,000 USD 84%
Accrued Liabilities, Current $78,000 USD -79%
Liabilities, Current $921,000 USD 12%
Liabilities $921,000 USD 12%
Retained Earnings (Accumulated Deficit) $923,729,000 USD -0.44%
Stockholders' Equity Attributable to Parent $2,803,000 USD 2.9%
Liabilities and Equity $3,724,000 USD 4.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $772,000 USD 60%
Net Cash Provided by (Used in) Financing Activities $0 USD
Net Cash Provided by (Used in) Investing Activities $0 USD
Common Stock, Shares Authorized 50,000,000 shares 900%
Common Stock, Shares, Issued 2,205,846 shares 38%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $772,000 USD 60%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $1,938,000 USD 15%
Interest Paid, Excluding Capitalized Interest, Operating Activities $0 USD
Deferred Tax Assets, Valuation Allowance $213,281,000 USD 1.1%
Deferred Tax Assets, Gross $213,281,000 USD 1.1%
Depreciation $2,000 USD -100%
Payments to Acquire Property, Plant, and Equipment $0 USD -100%
Property, Plant and Equipment, Gross $15,000 USD 0%
Operating Lease, Weighted Average Discount Rate, Percent 0 pure
Deferred Tax Assets, Operating Loss Carryforwards $154,634,000 USD 4.5%
Deferred Tax Assets, Net of Valuation Allowance $0 USD
Interest Expense $0 USD -100%